T1	Participants 134 165	large hepatocellular carcinoma]
T2	Participants 350 381	hepatocellular carcinoma (HCC).
T3	Participants 390 432	Sixty-eight patients with unresectable HCC
T4	Participants 730 760	patients with multiple lesions
